Reports Q4 revenue $13.1M, consensus $5.66M. “Tarsus is establishing the next category in eye care and these strong results reflect our team’s ability to execute and deliver on our mission to bring revolutionary new medicines to patients,” said Bobak Azamian, CEO. “2024 is off to a great start, driven by the approval, launch and rapid uptake of XDEMVY, and the momentum we’ve already established is setting the tone for what we expect to be an impactful year ahead.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TARS:
- Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
- Is TARS a Buy, Before Earnings?
- Tarsus Pharmaceuticals announces results from Carpo, phase 2a trial of TP-05
- Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
- Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
